Volkswagen FY Preliminary Group Sales In Line With Its Forecast

Volkswagen (VKW.L,VLKAF.PK,VOW.BE) reported that its preliminary group sales for fiscal year 2022 were in line with its forecast, but net cash flow was significantly below its target.

The company reported group sales of 279 billion euros in fiscal year 2022, compared to the previous estimation of 8%-13% above prior-year figure of 250.2 billion euros.

Group operating profit before special items was around 22.5 billion euros. The expected return on sales were at around 8.1%. The company's previous outlook for return on sales in 2022 were 7.0%-8.5% of Group sales.

Net liquidity of the Automotive Division at December 31, 2022 was about 43 billion euros, including around 16 billion cash inflows from the IPO of Porsche AG conducted in September 2022.

Volkswagen's net cash flow was around 5 billion euros in fiscal 2022, falling short of its target of achieving net cash flow at the level of the previous year's 8.6 billion euros. The deviation was mainly due to the unstable supply situation throughout 2022 and disruptions in the logistics chains, particularly at the end of the year.

As a result, working capital and in particular inventories of finished goods, raw materials and supplies at the end of the year were significantly higher than expected.

Current planning for 2023 suggests that this year-end 2022 increase in working capital will largely reverse during the year.

Volkswagen plans to publish its annual report on March 14, 2023.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT